TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7822659

Group type: COMPARATOR
Intervention: Oral prednisone tapered over 8 days with intramuscular placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone sodium acetate and oral placebo
Number of subjects: 26
Study: 2120986

Group type: EXPERIMENTAL
Intervention: ioversol-320 (32 g iodine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: iohexol-300 (45 g iodine)
Number of subjects: 200
Study: 646497

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (Group A: 18 patients, Group C: 6 patients)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard nonoperative measures (Group B: 61 patients) and early operation (Group D: 18 patients)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (Group A and C)
Number of subjects: 103
Study: 31937355

Group type: EXPERIMENTAL
Intervention: VR-Spirit intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active control group (VR-training with standard games)
Number of subjects: 42
Study: 30649973

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (P + C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab (P)
Number of subjects: 0
Study: 29070849

Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapies
Number of subjects: 100
Study: 25736286

Group type: EXPERIMENTAL
Intervention: 3D-HD video system
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2D-HD video system
Number of subjects: 18
Study: 23574571

Group type: EXPERIMENTAL
Intervention: Anti-wrinkle cream containing retinol, hyaluronic acid, and dihydroxymethylchromone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 21059877

Group type: EXPERIMENTAL
Intervention: RME followed by TPA therapy plus extraction of deciduous canines (RME/TPA/EC group, 40 subjects)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TPA therapy plus extraction of deciduous canines (TPA/EC group, 25 subjects)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Extraction of deciduous canines (EC group, 25 subjects)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No orthodontic treatment (Control group, CG, 30 subjects)
Number of subjects: 120
Study: 19935017

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 20551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20551
Study: 17076946

Group type: EXPERIMENTAL
Intervention: Oral polyethylene glycol (PEG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 36
Study: 14571072

Group type: EXPERIMENTAL
Intervention: Educational intervention conducted by trained teachers using ad hoc developed materials.
Number of subjects: 4233

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 4233
Study: 10880165

Group type: EXPERIMENTAL
Intervention: Ademetionine for four weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Potassium magnesium aspartate for four weeks
Number of subjects: 110
Study: 8932837

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by autologous bone marrow transplantation (ABMT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg), mitoxantrone (60 mg/m2), and melphalan (140 mg/m2) followed by ABMT
Number of subjects: 61
Study: 1559530

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: EMG Biofeedback
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ST Biofeedback
Number of subjects: 81

Group type: COMPARATOR
Intervention: No Biofeedback
Number of subjects: 81

Group type: COMPARATOR
Intervention: No RT
Number of subjects: 81
Study: 3887165

Group type: EXPERIMENTAL
Intervention: Muscle paralysis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no muscle paralysis)
Number of subjects: 24
Study: 31101371

Group type: EXPERIMENTAL
Intervention: Industry-funded trials
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Statistically significant subgroup analysis
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Claiming accomplishment of an objective not prespecified
Number of subjects: 114
Study: 31481105

Group type: EXPERIMENTAL
Intervention: Remission achieved and maintained
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Clinical atherosclerosis
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: High blood pressure
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: ACPA
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Mean values of CRP during follow-up
Number of subjects: 841
Study: 28505956

Group type: EXPERIMENTAL
Intervention: Non‐invasive Spinal Decompression Therapy (NSDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of electrotherapy, deep friction massage, and stabilization exercise (Control Group)
Number of subjects: 20
Study: 25384624

Group type: EXPERIMENTAL
Intervention: Split virion vaccine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Whole virion vaccine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Split virion vaccine with anti-TNF-α therapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Postimmunization
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 156
Study: 23068310

Group type: EXPERIMENTAL
Intervention: sucking-oral sucrose-tucking
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: sucking-oral sucrose
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: oral sucrose-tucking
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: sucking-tucking
Number of subjects: 110

Group type: COMPARATOR
Intervention: routine care
Number of subjects: 110
Study: 21805066

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 129

Group type: COMPARATOR
Intervention: Roxatidine
Number of subjects: 129
Study: 19366972

Group type: EXPERIMENTAL
Intervention: Intravenous glulisine insulin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subcutaneous glargine and glulisine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subcutaneous NPH and regular insulin
Number of subjects: 68
Study: 16738027

Group type: EXPERIMENTAL
Intervention: Empathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empathy in ingroup condition
Number of subjects: 0
Study: 15305945

Group type: EXPERIMENTAL
Intervention: Withdrawal of inhaled budesonide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous treatment with inhaled budesonide
Number of subjects: 18
Study: 11321648

Group type: EXPERIMENTAL
Intervention: Days of raised geomagnetic activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Days of little or no sun activity (quiet sun)
Number of subjects: 0
Study: 9386112

Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin (0.1 U/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blinded vasopressin (in crossover subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vasopressin in low vasopressin group (n=5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vasopressin in high vasopressin group (n=3)
Number of subjects: 10
Study: 7910053

Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin alpha 1, interferon-alpha, and zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine alone or associated with single agents
Number of subjects: 0
Study: 3064642

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 mg/day) for 10 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo capsules for 10 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Alcoholics with subnormal serum alpha-tocopherol
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Alcoholics and controls
Number of subjects: 69
Study: 29347848

Group type: EXPERIMENTAL
Intervention: Intravaginal oxytocin gel
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 140
Study: 26514296

Group type: EXPERIMENTAL
Intervention: Neck-specific exercises (NSEs)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 41
Study: 24793567

Group type: EXPERIMENTAL
Intervention: Prednisone, 60mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24173178

Group type: EXPERIMENTAL
Intervention: 3% diclofenac sodium
Number of subjects: 28

Group type: COMPARATOR
Intervention: 5% 5-Fluorouracil
Number of subjects: 28
Study: 20921032

Group type: EXPERIMENTAL
Intervention: Higher-intensity treadmill walking (30 minutes, three times per week for six weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 30
Study: 19595100

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation technique (navigation group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional anatomic landmark technique (conventional group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: General fitness rate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Screw canal preparation time
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 95
Study: 17046545

Group type: EXPERIMENTAL
Intervention: Structured triglyceride (STG) emulsion (Structolipid 20%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Long-chain fatty acid triglyceride (LCT) emulsion (Intralipid 20%)
Number of subjects: 8
Study: 12734858

Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 83
Study: 10647721

Group type: EXPERIMENTAL
Intervention: 0.5 ml intracameral, unpreserved, epinephrine‐free 1% lidocaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9052889

Group type: EXPERIMENTAL
Intervention: Intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 mL per minute)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-arginine (1 micromol/100 mL per minute)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 microg/100 mL per minute)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1, 2, and 4 microg/100 mL per minute)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 90
Study: 8346005

Group type: EXPERIMENTAL
Intervention: Trivalent cold‐adapted recombinant influenza vaccine
Number of subjects: 68
Study: 2954872

Group type: EXPERIMENTAL
Intervention: Buddy programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 29880148

Group type: EXPERIMENTAL
Intervention: Sleep extension (EXT)
Number of subjects: 18
Study: 26549496

Group type: EXPERIMENTAL
Intervention: Magnetic attachment (group I, GI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Locator attachment (group II, GII)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (GI and GII)
Number of subjects: 32
Study: 25394440

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (50 μg) and normal saline (10 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural fentanyl (50 μg) and bupivacaine (0.5%; 10 mL)
Number of subjects: 50
Study: 23328343

Group type: EXPERIMENTAL
Intervention: Multidisciplinary program consisting of cognitive-behavior therapy and exercise training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 90
Study: 16154423

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 12858034

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9469675

Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered under fasting conditions (treatment A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered directly after a standard high-fat breakfast (treatment B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg administered 2 hours after a standard high-fat breakfast (treatment C)
Number of subjects: 8
Study: 8674522

Group type: EXPERIMENTAL
Intervention: Counseling program for family caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional counseling dimensions (education, emotional expressiveness)
Number of subjects: 0
Study: 1964073

Group type: EXPERIMENTAL
Intervention: CEV (etoposide + vindesine + cisplatin)
Number of subjects: 201

Group type: COMPARATOR
Intervention: EV (etoposide + vindesine)
Number of subjects: 201
Study: 369966

Group type: EXPERIMENTAL
Intervention: Native gammaglobulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-treated gammaglobulin
Number of subjects: 0
Study: 28614492

Group type: EXPERIMENTAL
Intervention: rTMS applied over the right DLPFC (1 Hz, n=15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: rTMS applied over the left DLPFC (5 Hz, n=14)
Number of subjects: 29
Study: 27424688

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 22 mg/kg/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 81
Study: 24729492

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study: 24246459

Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare (FPH) CPAP interface
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hudson CPAP interface
Number of subjects: 20
Study: 20430115

Group type: EXPERIMENTAL
Intervention: Usual primary prevention care plus bespoke lifestyle support (treatment)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Usual primary prevention care (control)
Number of subjects: 920
Study: 18645188

Group type: EXPERIMENTAL
Intervention: Transient ischemic cutaneous anesthesia of the healthy hand
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy foot (control intervention)
Number of subjects: 10
Study: 15824870

Group type: EXPERIMENTAL
Intervention: Right, left, and biventricular stimulation at different AV delays
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Atrial-left ventricular stimulation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Atrial-biventricular stimulation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Follow-up after one year
Number of subjects: 188
Study: 12438948

Group type: EXPERIMENTAL
Intervention: Sirolimus (5 mg daily after a 15 mg loading dose, concentration-controlled to keep 24-hr trough levels at 10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cyclosporine (6 to 8 mg/kg per day in divided doses, concentration-controlled to keep 12-hr troughs of 200 to 250 ng/mL)
Number of subjects: 61
Study: 12198790

Group type: EXPERIMENTAL
Intervention: Tickling by the experimenter
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tickling by an automated machine
Number of subjects: 35
Study: 7781416

Group type: EXPERIMENTAL
Intervention: Surgery combined with chemotherapy and radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 2201320

Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control colostrum
Number of subjects: 5
Study: 6104451

Group type: EXPERIMENTAL
Intervention: KWD 2131 (0.5 mg to 12 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Terbutaline (0.05 mg to 1.2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 8
Study: 29594368

Group type: EXPERIMENTAL
Intervention: Individually delivered social competence training (THAV)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Active control (PLAY)
Number of subjects: 91
Study: 28239805

Group type: EXPERIMENTAL
Intervention: Closed-loop target controlled infusion (CLTCI) of cisatracurium
Number of subjects: 150

Group type: COMPARATOR
Intervention: Muscle relaxation monitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Continuous pump injection
Number of subjects: 150
Study: 25646323

Group type: EXPERIMENTAL
Intervention: Stable foam (SF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Less-stable foam (LSF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Liquid control (LC)
Number of subjects: 18
Study: 23332034

Group type: EXPERIMENTAL
Intervention: Orbicularis oculi muscle stripping
Number of subjects: 10

Group type: COMPARATOR
Intervention: Skin-only blepharoplasty
Number of subjects: 10
Study: 19966583

Group type: EXPERIMENTAL
Intervention: Slow-velocity (30° · s(‐1)) maximal lengthening contractions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (single bout of fast-velocity exercise)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Repeated bout group (first bout at 30° · s(‐1) and second bout at 210° · s(‐1))
Number of subjects: 18
Study: 19436665

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (general)
Number of subjects: 0
Study: 17364735

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 353
Study: 15545949

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/S) combination
Number of subjects: 520

Group type: COMPARATOR
Intervention: Treatment with a free combination of an inhaled corticosteroid and a long-acting beta2-agonist (TA)
Number of subjects: 520
Study: 11489827

Group type: EXPERIMENTAL
Intervention: c-erbB-2 gene amplification
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Relative increase in c-erbB-2 gene copy number
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Gain of chromosome 17
Number of subjects: 29
Study: 9731837

Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 intracervical gel (Prepidil) every 6 hours for 2 doses
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg prostaglandin E2 slow release vaginal pessary (Cervidil)
Number of subjects: 90
Study: 7984606

Group type: EXPERIMENTAL
Intervention: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals, 10 sessions using a YAVOR device at 6.4 and 7.1 mm.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (drug therapy alone).
Number of subjects: 54
Study: 2722718

Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cefmetazole 2 g
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 29
Study: 798282

Group type: EXPERIMENTAL
Intervention: Early splenectomy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cyclic chemotherapy with Arabinosyl Cytosine (ARA C), Vincristine, and Prednisone
Number of subjects: 139

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 139
Study: 29574988

Group type: EXPERIMENTAL
Intervention: Postoperative pain management educational intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Non-pharmacological methods
Number of subjects: 152
Study: 28132007

Group type: EXPERIMENTAL
Intervention: ibobbly app (acceptance‐based therapy) over 6 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: waitlist for 6 weeks then ibobbly app for 6 weeks
Number of subjects: 61
Study: 26346724

Group type: EXPERIMENTAL
Intervention: Pirarubicin plus capecitabine (AX regimen)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Pirarubicin plus cyclophosphamide (AC regimen)
Number of subjects: 280
Study: 23399428

Group type: EXPERIMENTAL
Intervention: EGFR mutations
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 151
Study: 20823239

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 18059502

Group type: EXPERIMENTAL
Intervention: sildenafil 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 16825049

Group type: EXPERIMENTAL
Intervention: Morselized rib graft (Group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Titanium interbody cages (Group B)
Number of subjects: 15
Study: 12707659

Group type: EXPERIMENTAL
Intervention: Acyclovir and hydrocortisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 60
Study: 11134566

Group type: EXPERIMENTAL
Intervention: K(+)‐adsorption filter
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no filter)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 8971288

Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine 150 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine 300 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard ranitidine 150 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard ranitidine 300 mg
Number of subjects: 15
Study: 1467076

Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline (HS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: isotonic saline (NS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 30
Study: 6360571

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) applied and adjusted from 4 cm H2O to a level that obliterated snoring.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control night (no CPAP treatment).
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nasal CPAP (range 4 to 13 cm H2O).
Number of subjects: 9